Deep Track Capital
Latest statistics and disclosures from Deep Track Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AMGN, ARGX, AXSM, DYN, SWTX, and represent 23.32% of Deep Track Capital's stock portfolio.
- Added to shares of these 10 stocks: IMVT (+$63M), APLS (+$58M), TGTX (+$51M), AXSM (+$44M), ARGX (+$43M), GPCR (+$36M), IONS (+$30M), ELYM (+$28M), KRRO (+$26M), FDMT (+$22M).
- Started 11 new stock positions in ETNB, ELYM, EWTX, AGEN, CNTX, INO, PRAX, CYTK, TGTX, KRRO. KURA.
- Reduced shares in these 10 stocks: INSM (-$187M), ALNY (-$81M), GERN (-$74M), APGE (-$52M), GH (-$43M), TRML (-$37M), , ANIP (-$23M), NUVL (-$21M), DYN (-$20M).
- Sold out of its positions in Agenus, ANAB, MRSN, NUVL, PACB, PRME, TRML, RARE.
- Deep Track Capital was a net seller of stock by $-42M.
- Deep Track Capital has $3.4B in assets under management (AUM), dropping by -4.03%.
- Central Index Key (CIK): 0001856083
Tip: Access up to 7 years of quarterly data
Positions held by Deep Track Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Deep Track Capital
Deep Track Capital holds 68 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Amgen (AMGN) | 5.4 | $180M | +4% | 575k | 312.45 |
|
| Argenx Se Sponsored Adr (ARGX) | 5.1 | $172M | +33% | 400k | 430.04 |
|
| Axsome Therapeutics (AXSM) | 4.5 | $149M | +42% | 1.9M | 80.50 |
|
| Dyne Therapeutics (DYN) | 4.2 | $141M | -12% | 4.0M | 35.29 |
|
| Springworks Therapeutics (SWTX) | 4.2 | $139M | +6% | 3.7M | 37.67 |
|
| Insmed Com Par $.01 (INSM) | 4.0 | $134M | -58% | 2.0M | 67.00 |
|
| Guardant Health (GH) | 3.9 | $130M | -25% | 4.5M | 28.88 |
|
| Dynavax Technologies Corp Com New (DVAX) | 3.7 | $122M | +19% | 11M | 11.23 |
|
| Alnylam Pharmaceuticals (ALNY) | 3.6 | $122M | -39% | 500k | 243.00 |
|
| Intellia Therapeutics (NTLA) | 3.2 | $107M | +13% | 4.8M | 22.38 |
|
| Intra Cellular Therapies (ITCI) | 3.1 | $105M | -8% | 1.5M | 68.49 |
|
| Apellis Pharmaceuticals (APLS) | 2.9 | $96M | +150% | 2.5M | 38.36 |
|
| Ionis Pharmaceuticals (IONS) | 2.8 | $95M | +45% | 2.0M | 47.66 |
|
| Ocular Therapeutix (OCUL) | 2.6 | $87M | 13M | 6.84 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 2.5 | $85M | +33% | 4.1M | 20.99 |
|
| Alkermes SHS (ALKS) | 2.5 | $84M | 3.5M | 24.10 |
|
|
| Nurix Therapeutics (NRIX) | 2.5 | $83M | +33% | 4.0M | 20.87 |
|
| Immunovant (IMVT) | 2.3 | $76M | +484% | 2.9M | 26.40 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 2.1 | $71M | 3.5M | 20.24 |
|
|
| Pliant Therapeutics (PLRX) | 1.9 | $64M | +3% | 6.0M | 10.75 |
|
| Travere Therapeutics (TVTX) | 1.8 | $61M | 7.4M | 8.22 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 1.7 | $58M | +25% | 4.0M | 14.46 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.6 | $55M | -2% | 4.2M | 13.22 |
|
| Geron Corporation (GERN) | 1.6 | $55M | -57% | 13M | 4.24 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 1.6 | $53M | 15M | 3.48 |
|
|
| Tg Therapeutics (TGTX) | 1.5 | $51M | NEW | 2.9M | 17.79 |
|
| Miragen Therapeutics (VRDN) | 1.5 | $51M | +13% | 3.9M | 13.01 |
|
| Kymera Therapeutics (KYMR) | 1.3 | $45M | +18% | 1.5M | 29.85 |
|
| Mind Medicine Mindmed Com New (MNMD) | 1.3 | $44M | -8% | 6.1M | 7.21 |
|
| Olema Pharmaceuticals (OLMA) | 1.3 | $43M | +24% | 4.0M | 10.82 |
|
| Terns Pharmaceuticals (TERN) | 1.2 | $42M | 6.1M | 6.81 |
|
|
| Spyre Therapeutics Com New (SYRE) | 1.2 | $41M | +44% | 1.8M | 23.51 |
|
| Apogee Therapeutics (APGE) | 1.2 | $39M | -56% | 1.0M | 39.35 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.1 | $37M | +2266% | 950k | 39.27 |
|
| Biosante Pharmaceuticals (ANIP) | 0.9 | $30M | -43% | 466k | 63.68 |
|
| Editas Medicine (EDIT) | 0.8 | $28M | +8% | 6.0M | 4.67 |
|
| Eliem Therapeutics (ELYM) | 0.8 | $28M | NEW | 3.9M | 7.11 |
|
| Hillevax (HLVX) | 0.8 | $27M | -28% | 1.8M | 14.46 |
|
| Korro Bio (KRRO) | 0.8 | $26M | NEW | 771k | 33.87 |
|
| Silence Therapeutics Ads (SLN) | 0.8 | $26M | -17% | 1.4M | 19.00 |
|
| Nektar Therapeutics (NKTR) | 0.7 | $22M | -2% | 18M | 1.24 |
|
| Engene Holdings (ENGN) | 0.6 | $21M | 2.3M | 9.43 |
|
|
| Alector (ALEC) | 0.6 | $21M | +22% | 4.6M | 4.54 |
|
| 89bio (ETNB) | 0.5 | $18M | NEW | 2.3M | 8.01 |
|
| Fate Therapeutics (FATE) | 0.5 | $18M | 5.6M | 3.28 |
|
|
| Inovio Pharmaceuticals Com Shs (INO) | 0.5 | $17M | NEW | 2.1M | 8.08 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.5 | $16M | NEW | 390k | 41.36 |
|
| Cybin Ord (CYBN) | 0.5 | $16M | 58M | 0.27 |
|
|
| Context Therapeutics (CNTX) | 0.4 | $15M | NEW | 7.4M | 2.00 |
|
| Pyxis Oncology Common Stock (PYXS) | 0.4 | $14M | 4.2M | 3.31 |
|
|
| Adagio Therapeutics (IVVD) | 0.4 | $12M | 11M | 1.10 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 0.3 | $12M | +30% | 3.3M | 3.50 |
|
| Kura Oncology (KURA) | 0.2 | $7.9M | NEW | 385k | 20.59 |
|
| Cytokinetics Com New (CYTK) | 0.2 | $7.2M | NEW | 133k | 54.18 |
|
| Regulus Therapeutics (RGLS) | 0.2 | $5.8M | 3.3M | 1.78 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 0.2 | $5.5M | -14% | 512k | 10.69 |
|
| Agenus Com New (AGEN) | 0.2 | $5.2M | NEW | 313k | 16.75 |
|
| Allakos (ALLK) | 0.1 | $5.0M | 5.0M | 1.00 |
|
|
| Syros Pharmaceuticals Com New (SYRS) | 0.1 | $4.3M | 829k | 5.16 |
|
|
| Relmada Therapeutics (RLMD) | 0.1 | $3.7M | 1.2M | 3.00 |
|
|
| Edgewise Therapeutics (EWTX) | 0.1 | $3.4M | NEW | 186k | 18.01 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.1 | $3.1M | -45% | 373k | 8.33 |
|
| Repare Therapeutics Ord (RPTX) | 0.1 | $3.0M | -66% | 904k | 3.30 |
|
| Cogent Biosciences (COGT) | 0.1 | $2.6M | -2% | 308k | 8.43 |
|
| Vigil Neuroscience (VIGL) | 0.1 | $2.4M | -62% | 597k | 4.00 |
|
| Aligos Therapeutics (ALGS) | 0.1 | $2.1M | 6.1M | 0.35 |
|
|
| Metagenomi (MGX) | 0.1 | $1.9M | 466k | 4.08 |
|
|
| Neumora Therapeutics Call Option (NMRA) | 0.1 | $1.8M | -81% | 181k | 9.83 |
|
Past Filings by Deep Track Capital
SEC 13F filings are viewable for Deep Track Capital going back to 2021
- Deep Track Capital 2024 Q2 filed Aug. 14, 2024
- Deep Track Capital 2024 Q1 filed May 15, 2024
- Deep Track Capital 2023 Q4 filed Feb. 14, 2024
- Deep Track Capital 2023 Q3 filed Nov. 14, 2023
- Deep Track Capital 2023 Q2 restated filed Sept. 6, 2023
- Deep Track Capital 2023 Q2 filed Aug. 14, 2023
- Deep Track Capital 2023 Q1 filed May 15, 2023
- Deep Track Capital 2022 Q4 filed Feb. 14, 2023
- Deep Track Capital 2022 Q3 filed Nov. 14, 2022
- Deep Track Capital 2022 Q2 filed Aug. 12, 2022
- Deep Track Capital 2022 Q1 filed May 16, 2022
- Deep Track Capital 2021 Q4 filed Feb. 14, 2022